Tretten Approval History
- FDA approved: Yes (First approved December 23rd, 2013)
- Brand name: Tretten
- Generic name: coagulation factor XIII A-subunit (recombinant)
- Company: Novo Nordisk
- Treatment for: Factor XIII A-Subunit Deficiency
Tretten (coagulation factor XIII A-subunit (recombinant)) is a recombinant analogue of the human Factor XIII A-subunit for the prevention of bleeding in patients who have the rare clotting disorder congenital Factor XIII A-subunit deficiency.
Development History and FDA Approval Process for Tretten
|Dec 23, 2013||FDA Approves Tretten to Treat Rare Genetic Clotting Disorder|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.